3SKIN AS

3SKIN AS is a Norwegian skincare company based in Oslo that develops sun-care products built on decades of skin-cancer and photodynamic-therapy (PDT) research. Its flagship proposition is a triple-action sunscreen with SPF 50+ that the company says protects against further UV damage, interacts with skin-renewal-related processes, and has shown favorable trends in investigator-assessed skin structural parameters in exploratory analyses. The brand positions itself at the intersection of dermatological science and everyday sun protection, summarised in its own values as "Driven by science. Designed for living." The company was founded by three physicians who are described as pioneers in PDT and 5-aminolevulinic acid (5-ALA) research: Dr. Ana Maria Solér, Dr. Qian Peng and Dr. Trond Warloe. According to the company, the founders have more than 85 years of combined experience in the clinical treatment and scientific research of skin cancer, and they previously invented patents for Photocure that have been used in treating skin-cancer and sun-damaged patients worldwide. Their work included stabilising 5-ALA at room temperature. The founding impulse is presented as clinical frustration: Dr. Solér repeatedly saw patients with sun-damaged skin undergoing harsh treatments, and became convinced there had to a better way to treat — and above all prevent — the problem. Combining their inventions with what the company calls the best available sunscreen, the team created 3SKIN. 3SKIN's product is under clinical investigation. The company reports an independent, double-blinded, randomised clinical study with 80 participants (10 healthy), conducted from August to December 2024 over three months (± two weeks) in Oslo, Norway, with one principal investigator and two independent dermatologists performing photo review. The study was approved by the Norwegian Data Protection Authority (DMP) and an ethical council, used a VISIA scanner for standardised photography, and was fully monitored by an independent CRO, with Cutometer and ultrasound measurements. Reported endpoints include actinic keratosis severity, skin elasticity and firmness, skin thickness, wrinkle reduction, fewer AK lesions, overall skin improvement and higher treatment satisfaction than placebo; the company frames these as favorable trends under clinical investigation, and states the results are to be published. Before-and-after images shown on the site come from a prior exploratory clinical investigation of 5-ALA and vitamin D₃ in a sunscreen formulation and are presented for scientific illustration only. The brand's stated values are grounded in science, made for people; pioneering with purpose; safe by nature, proven by medicine; and freedom in the sun. Its active natural ingredients are paired with medical validation and clinical documentation. 3SKIN operates from Oslo and, as of the available evidence, markets primarily in Norway through its own website. Ownership, funding and corporate structure beyond the AS (limited company) form are not disclosed in the available sources.

3SKIN AS was founded in Oslo, Norway, by three physicians with deep roots in dermatological research: Dr. Ana Maria Solér, Dr. Qian Peng and Dr. Trond Warloe. The company's own account traces its origin to clinical practice rather than to a laboratory idea. Dr. Solér repeatedly treated patients suffering from sun-damaged skin who had to undergo harsh treatment again and again, and she became convinced that there had to be a better way to treat them — and, more importantly, to prevent the damage from occurring in the first place. The founders were not newcomers to the field. They are described as pioneers in photodynamic therapy (PDT) and 5-aminolevulinic acid (5-ALA), with more than 85 years of combined experience in the clinical treatment and scientific research of skin cancer. Together they had invented patents for Photocure, a company whose technologies have since been used in the treatment of skin-cancer and sun-damaged patients worldwide. Their research team also achieved further scientific advances by stabilising 5-ALA at room temperature, a step that matters for making light-activated dermatological treatments practical outside specialised cold-chain settings. Building on that body of work, the founders combined their inventions with what they describe as the best sunscreen available, creating 3SKIN: a sunscreen that is under clinical investigation with the intention of repairing UV-damaged skin while also improving skin elasticity and skin health over time — simply by being outside. The brand frames this as translating decades of cancer research into a simple, safe, everyday product. The company's clinical programme is central to its history and identity. 3SKIN reports an independent, double-blinded, randomised clinical study with 80 participants (10 of them healthy), conducted between August and December 2024 over a period of three months (± two weeks) in Oslo, Norway. The study had one principal investigator and two independent dermatologists conducting photo review, was approved by the Norwegian Data Protection Authority (DMP) and an ethical council, used a VISIA scanner for standardised photographs under the same lighting, and was fully monitored by an independent CRO, with Cutometer and ultrasound measurements. Reported endpoints included actinic keratosis severity, skin elasticity and firmness, skin thickness, wrinkle reduction (fine lines), fewer AK lesions, overall skin improvement, improvement in AK lesions under dermoscopy, and higher treatment satisfaction than placebo. The company characterises these as favorable trends observed under clinical investigation and states that the results are to be published. Before-and-after images displayed by the brand come from a prior exploratory clinical investigation evaluating 5-ALA and vitamin D₃ in a sunscreen formulation, and are shown for scientific illustration rather than as guaranteed outcomes. As of the available evidence, 3SKIN remains a privately held Norwegian limited company (AS) headquartered in Oslo, selling through its own website and focused on the Norwegian market. No parent company, external owner, funding round or stock listing is disclosed in the sources.

• Founders Dr. Ana Maria Solér, Dr. Qian Peng and Dr. Trond Warloe pioneer photodynamic therapy and 5-ALA research and invent patents for Photocure.

• The team achieves scientific advances in stabilising 5-ALA at room temperature.

• 3SKIN is founded in Oslo, Norway, combining the founders' inventions with a sunscreen formulation.

• Independent double-blinded, randomised clinical study (n = 80, three months) conducted in Oslo from August to December 2024.

• Study results reported as favorable trends under clinical investigation, with publication pending.

Science-driven sun care that protects against UV damage while aiming to support skin renewal and structural skin health, developed by pioneers in photodynamic therapy and 5-ALA research.

• 3SKIN SPF 50+ triple-action sunscreen

  A sunscreen with high UV protection of SPF 50+ that the company says protects against further skin damage, interacts with skin-renewal-related mechanisms, and has shown favorable trends in investigator-assessed skin structural parameters in exploratory analyses. Under clinical investigation.

1. 13SKIN official website3skin.no
2. 23SKIN – About3skin.no
3. 33SKIN – Science and clinical results3skin.no
4. 4Wikidata: 3SKIN AS (Norway)wikidata.org